Juvenescence Secures $76M in Series B-1 Financing Led by M42 to Accelerate AI-Driven Drug Development

21 May 2025 – Ramsey, Isle of Man – Juvenescence Ltd., a clinical-stage biotech leveraging AI to target age-related diseases, has announced the successful first close of its Series B-1 financing round, raising $76 million. The round was led by Abu Dhabi-based M42, which also enters a strategic partnership with Juvenescence to advance AI-driven therapeutics.

The fresh capital will propel Juvenescence’s pipeline of age-related disease therapies into later-stage clinical trials, with the second tranche of the Series B-1 round expected to close in Q3 2025.

This financing follows the announcement of a landmark collaboration between Juvenescence and M42, aimed at establishing a cutting-edge drug development hub in Abu Dhabi. The initiative will merge M42’s capabilities in digital health, genomics, and clinical infrastructure with Juvenescence’s AI-enabled discovery platforms and drug development expertise.

A joint steering committee comprising senior executives from both firms will oversee the rollout of the partnership, which also includes plans to engage academic and global R&D collaborators in support of Abu Dhabi’s broader life sciences strategy.

Dr Richard Marshall CBE, CEO of Juvenescence, emphasized the strategic value of the partnership:
“Together, we are building a therapeutics pipeline that aims to improve the lives of millions. This investment and collaboration mark a significant leap toward making Abu Dhabi a global centre for life sciences innovation.”

Dr Fahed Al Marzooqi, CEO of M42 Integrated Health Solutions and acting CEO of AI Life Sciences, added:
“This alliance represents a major milestone in redefining healthcare through AI, with a shared goal of bringing transformative, precision therapies to patients worldwide.”